Stock Events

Stock Events

Day One Biopharmaceuticals 

$21.53
30
+$0.04+0.19% Wednesday 20:00
-$0.03-0.14%Wednesday 22:00Pre-market

Statistics

Day High
21.53
Day Low
21.53
52W High
21.53
52W Low
5.8
Volume
-
Avg. Volume
-
Mkt Cap
2.21B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

13MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
-0.63
-0.29
0.04
0.38
Expected EPS
-0.28312
Actual EPS
N/A

Financials

-72.81%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
262.32MRevenue
-190.99MNet Income

Analyst Ratings

21.50Average Price Target
The highest estimate is 21.50.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb is a leading biopharmaceutical company that competes with Day One in the oncology space, particularly in developing treatments for various cancers.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. is a global healthcare company that develops cancer drugs and immunotherapies, directly competing with Day One Biopharmaceuticals in the oncology market.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. is involved in the discovery, development, and manufacture of healthcare products including cancer treatments, making it a competitor in the oncology sector.
Novartis
NVS
Mkt Cap292.35B
Novartis AG focuses on patented medicines, including oncology drugs, and competes with Day One Biopharmaceuticals in research, development, and marketing of cancer treatments.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG, through its pharmaceuticals division, is engaged in the research and development of oncology drugs, competing with Day One in the cancer treatment market.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca PLC is a biopharmaceutical company that develops a range of oncology treatments, competing with Day One in the cancer drug development space.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, Inc. is known for its innovative therapies in areas including oncology, making it a competitor in the development of cancer treatments.
AMGEN
AMGN
Mkt Cap233.78B
Amgen Inc. is a biotechnology company focusing on human therapeutics, including oncology, which competes with Day One in the development of cancer treatments.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, Inc. is involved in the discovery, development, and commercialization of medicines for serious medical conditions, including oncology, competing with Day One.
Incyte
INCY
Mkt Cap25.21B
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics, including for oncology, making it a competitor in the cancer treatment market.

About

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Show more...
CEO
Mr. Charles N. York II, M.B.A.
Employees
181
Country
United States
ISIN
US23954D1090

Listings

BOATS
BOATS
DAWN.BOATS

0 Comments

Share your thoughts

FAQ

What is Day One Biopharmaceuticals stock price today?▼
The current price of DAWN is $21.53 USD — it has increased by +0.19% in the past 24 hours. Watch Day One Biopharmaceuticals stock price performance more closely on the chart.
What is Day One Biopharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Day One Biopharmaceuticals stocks are traded under the ticker DAWN.
Is Day One Biopharmaceuticals stock price growing?▼
DAWN stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Day One Biopharmaceuticals has showed a +185.17% increase.
What is Day One Biopharmaceuticals market cap?▼
Today Day One Biopharmaceuticals has the market capitalization of 2.21B
What is Day One Biopharmaceuticals revenue for the last year?▼
Day One Biopharmaceuticals revenue for the last year amounts to 262.32M USD.
What is Day One Biopharmaceuticals net income for the last year?▼
DAWN net income for the last year is -190.99M USD.
How many employees does Day One Biopharmaceuticals have?▼
As of September 06, 2026, the company has 181 employees.
In which sector is Day One Biopharmaceuticals located?▼
Day One Biopharmaceuticals operates in the Health & Wellness sector.
When did Day One Biopharmaceuticals complete a stock split?▼
Day One Biopharmaceuticals has not had any recent stock splits.
Where is Day One Biopharmaceuticals headquartered?▼
Day One Biopharmaceuticals is headquartered in Brisbane, United States.